GlassScriptPhysician profile
Henrietta C Caday
NPI 1598134348
$5,703.77
in general payments reported to CMS, 2019-2025
22 companies · $1,400 in 2025
The $1,400 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,720 · 2022: $781 · 2023: $399 · 2024: $404 · 2025: $1,400.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,524 · Travel and Lodging: $679.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,524.32 |
| Travel and Lodging | $678.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,349.13 | 2021-2024 | Xarelto |
| Boston Scientific Corporation | $972.85 | 2024-2025 | Watchman Access System, Watchman Flx, Bodyguardian |
| Novartis Pharmaceuticals Corporation | $649.52 | 2021-2025 | Leqvio |
| Amgen INC. | $416.20 | 2021-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $346.07 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $298.31 | 2021-2025 | Lokelma, Farxiga, Lynparza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $269.89 | 2021-2023 | Jardiance |
| Amarin Pharma, INC. | $252.32 | 2021-2022 | |
| Esperion Therapeutics, INC. | $230.93 | 2021-2024 | Nexletol |
| Merck Sharp & Dohme LLC | $200.17 | 2021-2025 | Verquvo |
| Astellas Pharma US INC | $188.02 | 2021 | |
| Cvrx, INC. | $109.04 | 2023-2024 | Barostim Neo System |
| Novo Nordisk INC | $102.18 | 2021-2025 | Wegovy, Ozempic |
| Pfizer INC. | $98.95 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $67.22 | 2021-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $41.59 | 2022-2023 | Reveal Linq |
| Abiomed | $32.41 | 2024 | Impella |
| Abbott Laboratories | $24.13 | 2021 | |
| Biosense Webster, INC. | $15.27 | 2021 | |
| Sanofi-Aventis U.S. LLC | $14.50 | 2021 | |
| Chiesi USA, INC. | $13.87 | 2022 | |
| G Medical Diagnostic Services, INC. | $11.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henrietta Caday listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.